<DOC>
	<DOCNO>NCT02939365</DOCNO>
	<brief_summary>The purpose study determine safety feasibility convert patient Belatacept monotherapy ( receive one immunosuppression drug ) , see percentage patient safely convert every 8 week administration Belatacept . Belatacept approve Food Drug Administration ( FDA ) kidney transplant recipient .</brief_summary>
	<brief_title>Precision Medicine Offers Belatacept Monotherapy</brief_title>
	<detailed_description>Patients belatacept fulfill entry criterion screen determine quiescent molecular immunologic profile kSORT uCRM . Patients screen negative 2 test undergo stepwise withdrawal first steroids MMF mTor inhibitor . Prior withdrawal 2 screen molecular test perform advancement next withdrawal phase perform negative . Patients maintain belatacept monotherapy quiescent kSORT uCRM elevate kSPOT transition q 8 week belatacept administration . Forty patient previously enrol belatacept base regimen minimum 7 year follow 4 transplant center maintain belatacept , antiproliferative ± steroid approach enrollment . Drug withdrawal steroid ( patient steroid ) antiproliferatives ( MPAs mTor inhibitor ) follow design show Study Schema . Patients continue stable 3 month belatacept monotherapy convert q 4 week q 8 week belatacept administration .</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Stable renal function GFR ≥ 35 ml/min No history acute rejection A spot urine protein creatinine ratio 0.5 less No DSA Entry : Biomarker criterion Blood kSORT urine CRM test quiescent entry follow drug withdrawal . A third biomarker KSPOT use assess patient achieve tolerance . Eligibility 8 week Belatacept Administration Trough level belatacept 4 week great 2 µg/ml Trough level belatacept 8 week equal great 1 µg/ml Patients &lt; eGFR ( 35 ml/min ) History rejection Protein/creatinine rate &gt; 0.5 Presence DSA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>